Announcing the new book by DermNet NZ

Download a FREE sample chapter



Author: Anoma Ranaweera B.V.Sc; PhD (Clinical Biochemistry, University of Liverpool, UK); Chief Editor: Dr Amanda Oakley, Dermatologist, Hamilton, New Zealand, August 2016.


In July 2015 the US FDA (Food and Drug Administration) approved sonidegib (Odomzo®; Novartis, New Jersey, USA) for the treatment of adult patients with locally advanced basal cell carcinoma (BCC).

The European Commission approved the use of sonidegib for basal cell carcinoma in August 2015. In June 2016, sonidegib was granted marketing authorisation in Switzerland for treatment of adults with advanced basal cell carcinoma. The drug is also approved in Australia. Additional regulatory submissions are being reviewed by health authorities worldwide.

What is sonidegib used for?

Sonidegib is indicated for the treatment of adult patients with locally advanced basal cell carcinoma that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy. 

How does sonidegib work?

Dosage and administration of sonidegib

Link to key clinical-trial evidence about sonidegib

Potential drug interactions with sonidegib

What are the adverse effects of sonidegib?

The most common (≥ 10%) adverse reactions associated with sonidegib treatment in clinical trials were:

Warnings and precautions

Use of sonidegib in pregnancy

Use of sonidegib in nursing mothers

Paediatric use of sonidegib

The safety and effectiveness of sonidegib has not been established in children (<18 years of age).

Geriatric use of sonidegib

Hepatic impairment and sonidegib

Renal impairment and sonidegib

Effect of sonidegib on age, sex, weight and race

Related information

Make a donation

Donate Today

Help us to update and maintain DermNet New Zealand

Submit your images

We are expanding our image library

Contact us

History of DermNet NZ

Watch Dr Amanda Oakley presenting 'The History Of DermNet NZ' at The International Society Of Teledermatology.

Subscribe to our mailing list

* indicates required
DermNet NZ Newsletter